BRISBANE, Australia, Oct. 16, 2023 /PRNewswire/ MGI, a company committed to building core tools and technology to lead life science, today announced support for an industry-driven graduate research project focused on developing sequencing-based surveillance monitoring of antimicrobial resistance in the water environment on the annual World Food Day. Echoing this year's World Food Day theme highlighting the essential role of water for the foundation of our food, the project is part of a collaboration between the University of Queensland, the University of Adelaide and MGI to develop innovative ways to reduce the adverse impacts of antimicrobial resistance in engineered or natural aquatic environments, potentially contributing to improved water quality and food safety. Expected to begin in January 2024 and now open for applications (click here to apply for the project) , the project aims to conduct wastewater surveillance to track the profiles of antibiotic resistant bacteria (ARB)
BRISBANE, Australia, Feb. 16, 2023 /PRNewswire/ GNOMIXis an Australian specialty molecular genetics laboratory and consultation service. Empowered by MGI's DNBSEQ platform, GNOMIX has been providing high-quality customised genetic services for national and international customers since 2020 including laboratory services, clinical trials, research projects, independent testing for commercialisation, food and agri-genomics, and consultancy to allied industries. Currently the clinical genomics landscape in Australia is strongly influenced by a couple of major players heavily driven by profit to provide a limited number of mainstream services. This results in the lack of availability and accessibility of technology and resources for small and medium customers, and more broadly, the stagnation of technological development. The mission of GNOMIX is to fill this gap and adapt to a wider base of customers with specific sequencing needs, budget, and timeframe. The GNOMIX laboratory located
SINGAPORE, Dec. 1, 2022 /PRNewswire/ MGI Tech Co. Ltd. (MGI), a company committed to building core tools and technology to lead life science, will join global and Asian cancer professionals at the ESMO Asia Congress 2022 taking place 2-4 December in Singapore. In addition, MGI will introduce a free trial campaign on its latest sequencer DNBSEQ-G99 for early users in APAC at the event(more details can be found here). At ESMO, MGI sets to showcase its MGISP-100 Automated Sample Preparation System and DNBSEQ-G99 Genetic Sequencer at Booth C209. Suitable for small and medium-sized research laboratories such as in hospitals, MGISP-100 provides an automated library package for the most popular applications such as breast cancer, lung cancer and more. Meanwhile, as one of the fastest sequencers among medium-to-low throughput sequencers globally, DNBSEQ-G99 was developed based on MGI's proprietary DNBSEQ technology and further enabled by innovations in biochemistry, optics, fluidics,
SHENZHEN, China, June 24, 2022 /PRNewswire/ MGI, a company committed to being a world-leading life science innovator, has been awarded a Silver Globee in the 14th Annual 2022 Golden Bridge Business and Innovation Awards for its innovative COVID-19 pandemic control and response efforts worldwide. Since the rise of COVID-19, MGI has taken an active part in the prevention and control of the pandemic in over 70 countries and regions worldwide, including South Africa, Serbia, Saudi Arabia, the United Arab Emirates, Canada, and Australia. From facilitating large-scale nucleic acid testing for the detection of the SARS-CoV-2 virus through providing MGI automation systems, to virus genome sequencing to inform the tracing and understanding of the epidemiology and virology of each variant, MGI's DNBSEQ sequencers , automation systems, and proprietary ATOPlex technology have been continuously put to work to combat the virus and keep communities safe. "MGI is honored to be recognized fo